0001723464-26-000016
SEC filingBioHarvest Sciences announces CEO transition: Dr. Zaki Rakib becomes CEO, Ilan Sobel joins Board to focus on D2C growth.
BioHarvest Sciences announced a strategic leadership transition on April 29, 2026. Dr. Zaki Rakib, Co-Founder and Executive Chairman, has assumed the role of Chief Executive Officer, consolidating leadership of R&D, Manufacturing, and Operations under the CDMO division. Ilan Sobel, who served as CEO since 2020, has transitioned to the Board of Directors with a focused mandate on advancing the D2C business. This change is designed to sharpen execution of the company's 'two-lens strategy' across its D2C and CDMO businesses. Dr. Rakib brings over 35 years of executive leadership experience and deep institutional knowledge, having previously scaled Terayon Communication Systems from inception to $380 million in annual revenue and a $7 billion market capitalization. Mr. Sobel led BioHarvest from pre-revenue to approximately $35 million in revenue in fiscal year 2025, establishing the company as a Nasdaq-listed growth platform. The board believes this unified structure will strengthen long-term competitive positioning and accelerate manufacturing scale.